Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Peterson

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)Mark Lebwohl, Andrew Blauvelt, Carle Paul, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
Neoplasia (New York, N.Y.)|December 18, 2017
Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor GrowthAnupama Pal, Michele Dziubinski, Marina Pasca Di Magliano, et al.
JAMA Dermatology|April 26, 2023
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional TrialsAmit Garg, Carla Zema, Valerie Ciaravino, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Secukinumab in Plaque PsoriasisKristian Reich, Richard B Warren, Mark Lebwohl, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)Mark Lebwohl, Andrew Blauvelt, Carle Paul, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
Neoplasia (New York, N.Y.)|December 18, 2017
Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor GrowthAnupama Pal, Michele Dziubinski, Marina Pasca Di Magliano, et al.
JAMA Dermatology|April 26, 2023
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional TrialsAmit Garg, Carla Zema, Valerie Ciaravino, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Secukinumab in Plaque PsoriasisKristian Reich, Richard B Warren, Mark Lebwohl, et al.
Pageof 3